| P2093 | author name string | C Pérez | |
| | V Martínez | |
| | Y Escobar | |
| | J Porta-Sales | |
| P2860 | cites work | Opioids for the management of breakthrough pain in cancer patients | Q24202962 |
| | Morphine and alternative opioids in cancer pain: the EAPC recommendations | Q24648711 |
| | Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). | Q32147934 |
| | Breakthrough pain: definition, prevalence and characteristics | Q33435886 |
| | Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy. | Q33970064 |
| | Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids | Q34048360 |
| | Indicators of drug-seeking aberrant behaviours: the feasibility of use in observational post-marketing cohort studies for risk management | Q34051869 |
| | Research guidelines for the Delphi survey technique. | Q34092057 |
| | Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. | Q34251507 |
| | Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care | Q34539972 |
| | Breakthrough cancer pain - still a challenge | Q36429904 |
| | Prevalence of pain in patients with cancer: a systematic review of the past 40 years | Q36758835 |
| | The Alberta Breakthrough Pain Assessment Tool for cancer patients: a validation study using a delphi process and patient think-aloud interviews | Q37051857 |
| | Management of breakthrough pain in patients with cancer. | Q37154731 |
| | The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. | Q37245357 |
| | Assessment and classification of cancer breakthrough pain: a systematic literature review | Q37710813 |
| | Integrated strategies for the successful management of breakthrough cancer pain | Q37843304 |
| | Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients | Q37912136 |
| | Fentanyl for breakthrough cancer pain: where are we? | Q38069179 |
| | Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature | Q38116663 |
| | Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain | Q39415383 |
| | Description and predictors of direct and indirect costs of pain reported by cancer patients | Q40607097 |
| | An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain | Q40797392 |
| | Accuracy of a Diagnostic Algorithm to Diagnose Breakthrough Cancer Pain as Compared With Clinical Assessment | Q40888915 |
| | Guidelines for the management of breakthrough pain in patients with cancer | Q43827105 |
| | Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain | Q44105804 |
| | The prevalence of episodic pain in cancer: a survey of hospice patients on admission | Q44221667 |
| | Emerging opioid abuse in terminal cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain | Q44331352 |
| | Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain | Q44344156 |
| | A cross-sectional study on prevalence of pain and breakthrough pain among an unselected group of outpatients in a tertiary cancer clinic | Q45213227 |
| | The Delphi technique in health sciences education research | Q46774512 |
| | Rapid-onset opioids for the treatment of breakthrough cancer pain: two cases of drug abuse. | Q47851937 |
| | Breakthrough cancer pain: an observational study of 1000 European oncology patients | Q48187569 |
| | Assessing the impact of breakthrough cancer pain | Q48857212 |
| | The management of breakthrough cancer pain--educational needs a European nursing survey. | Q51198934 |
| | A European survey of oncology nurse breakthrough cancer pain practices. | Q51329178 |
| | Pain as an early symptom in cancer. | Q51649827 |
| | A Canadian online survey of oncology nurses' perspectives on the management of breakthrough pain in cancer (BTPc). | Q53688646 |
| | Epidemiology and Pattern of Care of Breakthrough Cancer Pain in a Longitudinal Sample of Cancer Patients | Q59649189 |
| | Management of cancer pain: ESMO Clinical Practice Guidelines | Q60673753 |
| | A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain | Q79301299 |
| | How do nurses assess and manage breakthrough pain in specialist palliative care inpatient units? A multicentre study | Q82266361 |
| | [Cancer-related breakthrough pain] | Q84184108 |
| | Treatment of cancer pain: Spanish Society of Medical Oncology (SEOM) recommendations for clinical practice | Q84431168 |
| | How do nurses in specialist palliative care assess and manage breakthrough cancer pain? A multicentre study | Q86824590 |
| | Development and validation of the breakthrough pain assessment tool (BAT) in cancer patients | Q87754420 |
| P433 | issue | 9 | |
| P921 | main subject | cancer pain | Q3712728 |
| P304 | page(s) | 945-954 | |
| P577 | publication date | 2015-12-22 | |
| P1433 | published in | Clinical and Translational Oncology | Q15754324 |
| P1476 | title | Diagnosis and management of breakthrough cancer pain: Have all the questions been resolved? A Delphi-based consensus assessment (DOIRON) | |
| P478 | volume | 18 | |